ArticleRadiation oncology (London, England)2026
Outcomes of radiotherapy of hepatocellular carcinoma: a retrospective analysis.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTechnical advances and a better understanding of liver tolerance have changed the role of radiotherapy in the treatment of liver cancer. The goal of this retrospective study was to evaluate the outcomes of radiotherapy with curative intent in patients ineligible for surgery and palliative intent in patients with advanced disease.
methodsPatients were treated with stereotactic body radiotherapy (SBRT), hypofractionated radiotherapy, or conventionally fractionated radiotherapy. Patients with a solitary liver tumor, no vascular invasion, Child-Pugh class A, and no extrahepatic tumors at the time of radiotherapy were considered for radiotherapy with curative intent, and the remaining patients for radiotherapy with palliative intent. Kaplan-Meier statistics and Cox proportional hazards regression analyses were used to evaluate overall survival.
resultsBetween 04/2019 and 08/2022, 93 consecutive patients with hepatocellular carcinoma (HCC) were treated external beam radiotherapy in our department. A total of 94.6% of the patients had received prior treatment. The 1-, 2-, and 3-year overall survival rates of patients treated with curative intent (n = 33) were 100%, 76%, and 65%, respectively, and those treated with palliative intent (n = 60) 63%, 31%, and 11%, respectively. No acute radiation reactions of grade ≥ 3 (CTCAE v5.0) were observed.
conclusionsOur data confirm that radiotherapy is an effective treatment option with curative intent for selected patients ineligible for surgery, and with palliative intent for those with advanced disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.